Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NETWORK 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Burkitt Lymphoma 8Leukemia, Biphenotypic, Acute 5Leukemia, Myeloid, Acute 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Hydatidiform Mole 2Down Syndrome 2Urinary Bladder Neoplasms 1Rhabdoid Tumor 1Osteosarcoma 1Myeloproliferative Syndrome, Transient 1Multiple Myeloma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Graft vs Host Disease 1Congenital Abnormalities 1Chromosome 5q Deletion Syndrome 1Choriocarcinoma 1Childhood Acute Promyelocytic Leukemia With PML-RARA 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

pegaspargase 3merphos 3dexamethasone acetate 3dexamethasone 21-phosphate 3azathiopurine 3auricularum 3Vincristine 3Thioguanine 3Methotrexate 3Mercaptopurine 3Leucovorin 3Doxorubicin 3Dexamethasone 3Cytarabine 3Cyclophosphamide 3Calcium Dobesilate 3prednylidene 2deltacortene 2blinatumomab 2Radiotherapy 2Radiation 2Prednisone 2Prednisolone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Methylprednisolone 2Asparaginase 2calaspargase pegol 1asparaginase erwinia chrysanthemi recombinant 1Specimen Handling 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × merphos × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT01190930 2026-05-22

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Children's Oncology Group

Phase 3 Completed
9,350 enrolled 51 charts
LymphoidOther hematologic neoplasm

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡